巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Liquidia Corp

    LQDA
    4.010
    0.350
    9.56%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Liquidia Corp - 延遲價格・最後更新於 26/05 12:14
    最高位
    4.400
    最低位
    3.520
    開市價
    --
    前收市價
    3.660
    成交量(千)
    298.19
    成交額(百萬)
    10.51
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    258.02
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    7.778 - 2.250
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Liquidia Corp
    證券代碼
    LQDA.US
    所屬板塊
    Biotechnology
    公司業務
    Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
    發行量
    52435802
    公司總部
    419 Davis Drive, Suite 100
    公司網址
    https://www.liquidia.com
    公司電郵
    jason.adair@liquidia.com
    公司電話
    +1 919 328-4400
    暫無內容

    關於

    Liquidia Corp(LQDA.US)所屬的行業板塊為Biotechnology。
    Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
    詳細公司背景可參考: https://www.liquidia.com